ArticleAnnals of surgical oncology2026
Groin Recurrence Rates After Exclusive Indocyanine Green Sentinel Node-Mapping in Early-Stage Vulvar Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe current study aimed to assess oncologic safety with 24-month groin recurrence rates after the exclusive use of indocyanine green (ICG) for sentinel node (SLN) detection in early-stage, node-negative vulvar cancer.
methodsThis retrospective cohort study descriptively assessed consecutive patients with early (T1/2 < 4 cm) squamous vulvar cancer who underwent exclusive ICG-based inguinal sentinel node-mapping without radioactive tracer or blue dye.
resultsData of 49 patients encompassing 94 groins at risk were available for analysis. The SLN detection rate was 90.4% (85/94) per groin. In nine (9.6%) groins, ICG failed to identify the SLN. These patients subsequently underwent lateralized systematic lymphadenectomy. Among patients with unifocal disease and a negative SLN (63 groins at risk in 33 patients), the 24-month groin recurrence rate was 1.6% (one unilateral recurrence) per groin.
conclusionExclusive ICG-guided SLN-mapping demonstrated a low groin recurrence rate in early-stage node-negative vulvar cancer. The study results are within the range previously reported by the GROINSS-V study after a combined radioactive tracer and blue dye approach. These findings suggest that exclusive ICG-guided SLN-mapping is feasible and may provide oncologic outcomes comparable with those reported for conventional SLN-mapping in carefully selected patients with early-stage vulvar cancer treated at a tertiary care center.
Indexed as
Identifiers
42722941What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.